Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529156 | 0.90 | MAPK1 (0.38) | MEN1KMT2ABACE1AOC3 | |
| SCHEMBL2529691 | 0.89 | ALDH1A1 (0.41) | MEN1KMT2ATDP1L3MBTL1AOC3 | |
| SCHEMBL2532057 | 0.88 | CA2 (0.40) | MEN1KMT2ATDP1L3MBTL1SIRT5 | |
| SCHEMBL2525471 | 0.88 | ALDH1A1 (0.38) | MEN1KMT2ATDP1L3MBTL1SIRT5 | |
| SCHEMBL2528610 | 0.87 | L3MBTL1 (0.41) | MEN1KMT2ATDP1L3MBTL1SIRT5 | |
| SCHEMBL2529626 | 0.86 | KMT2A (0.40) | MEN1KMT2ATDP1L3MBTL1BACE1 | |
| SCHEMBL2528094 | 0.85 | GPR88 (0.35) | MEN1KMT2ATDP1L3MBTL1SIRT5 | |
| SCHEMBL2528158 | 0.84 | KMT2A (0.41) | MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL2526417 | 0.84 | KMT2A (0.46) | MEN1KMT2AL3MBTL1AOC3 | |
| SCHEMBL2529226 | 0.84 | KMT2A (0.40) | MEN1KMT2AL3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039501-B2 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2011-10-18 | — | — | US | disclosed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | MEN1 1126/4885KMT2A 2317/4885TDP1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.